Form 4: CVS Director Acquires Deferred Stock Units

CVS Health Corp. Director Alecia A. DeCoudreaux acquired 1,652.091 deferred stock units as part of her compensation plan.

Summary

• Alecia A. DeCoudreaux, a Director of CVS Health Corp. (CVS), acquired 1,652.091 Deferred Stock Units (DSUs).
• The transaction occurred on November 20, 2025.
• The DSUs were issued for the deferral of a semi-annual retainer, consistent with the Issuer's non-employee director compensation policy and the 2017 Incentive Compensation Plan.
• Each DSU is valued at $76.04, based on the market price.
• Each DSU is convertible into one share of CVS common stock in the future, as elected by the reporting person.
• Following this transaction, Alecia A. DeCoudreaux beneficially owns a total of 40,053.5157 Deferred Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While a routine compensation event, the acquisition of additional equity by a director, even if deferred, generally signals continued alignment with the company's long-term performance and shareholder interests.

Positives

• The acquisition of deferred stock units by a director aligns their interests with those of shareholders, as their compensation is tied to the company's future stock performance.
• The transaction is part of a pre-established compensation policy, indicating a structured approach to director remuneration.

Future Outlook

The deferred stock units are to be converted into shares of common stock and issued in the future, as elected by the reporting person, indicating a future conversion event.

Management Comments

• The deferred stock units were issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.

Industry Context

This transaction is a routine insider filing, common across publicly traded companies, reflecting standard non-employee director compensation practices where equity-based awards are used to align director interests with long-term shareholder value. Many companies in the healthcare and retail pharmacy sectors utilize similar equity compensation plans for their board members.

Comparison to Industry Standards

• The use of Deferred Stock Units (DSUs) for non-employee director compensation is a common practice among S&P 500 companies, including peers in the healthcare and retail sectors like UnitedHealth Group (UNH) or Walgreens Boots Alliance (WBA), which often grant equity awards to their directors to foster long-term alignment.
• The valuation of DSUs at market price for compensation purposes is standard, ensuring transparency and direct linkage to company performance, similar to how other large-cap companies structure their equity grants.

Corporate Governance

Related Party Transactions

• Issuance of 1,652.091 deferred stock units to Director Alecia A. DeCoudreaux as part of her compensation, consistent with the company's non-employee director compensation policy and the 2017 Incentive Compensation Plan.

Stakeholder Impact

• Shareholders: The transaction demonstrates continued alignment of director interests with shareholder value through equity-based compensation.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The deferred stock units will be converted into shares of common stock and issued in the future, as elected by the reporting person.

Key Dates

Keywords

CVS Health, CVS, Deferred Stock Units, DSU, Insider Transaction, Form 4, Director Compensation, Equity Compensation, Alecia A. DeCoudreaux